Correction: Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling

Correction: Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling

Bibliographic Details
Main Author:	The Staff
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140840/?tool=EBI

Similar Items

Correction: Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling.
Published: (2014-01-01)

Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.
by: Holly M Nguyen, et al.
Published: (2013-01-01)

Correction: Androgen Suppresses the Proliferation of Androgen Receptor-Positive Castration-Resistant Prostate Cancer Cells via Inhibition of Cdk2, CyclinA, and Skp2
by: The Staff
Published: (2014-01-01)

SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas.
by: Daniel Compagno, et al.
Published: (2007-01-01)

Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer
by: Filippos Koinis, et al.
Published: (2020-01-01)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
by: Lin Hui-Ping, et al.
Published: (2011-08-01)

Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer
by: Hess David, et al.
Published: (2010-05-01)

Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
by: Mark A Titus, et al.
Published: (2012-01-01)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
by: Qin Feng, et al.
Published: (2019-09-01)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
by: Mark N Stein, et al.
Published: (2014-06-01)

Ceramide Regulates Anti-Tumor Mechanisms of Erianin in Androgen-Sensitive and Castration-Resistant Prostate Cancers
by: I Gusti Md Gde Surya C. Trapika, et al.
Published: (2021-09-01)

Inhibition of castration resistant prostate cancer by sintokamide A : an antagonist of the amino-terminus of the androgen receptor
by: Tavakoli, Iran
Published: (2012)

Inhibition of castration resistant prostate cancer by sintokamide A : an antagonist of the amino-terminus of the androgen receptor
by: Tavakoli, Iran
Published: (2012)

Inhibition of castration resistant prostate cancer by sintokamide A : an antagonist of the amino-terminus of the androgen receptor
by: Tavakoli, Iran
Published: (2012)

Correction: Androgen Suppresses the Proliferation of Androgen Receptor-Positive Castration-Resistant Prostate Cancer Cells via Inhibition of Cdk2, CyclinA, and Skp2.
Published: (2014-01-01)

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
by: Daisuke Obinata, et al.
Published: (2020-10-01)

The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer
by: Jennifer H. Gunter, et al.
Published: (2012-01-01)

HE3235 Inhibits Growth of Castration-Resistant Prostate Cancer
by: Theodore D. Koreckij, et al.
Published: (2009-11-01)

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
by: Emma Hörnberg, et al.
Published: (2011-04-01)

Mechanisms behind growth of castration-resistant prostate cancer bone metastases
by: Jernberg, Emma
Published: (2013)

The AhR Ligand, TCDD, Regulates Androgen Receptor Activity Differently in Androgen-Sensitive versus Castration-Resistant Human Prostate Cancer Cells
by: Maryam Ghotbaddini, et al.
Published: (2015-07-01)

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
by: Li Q, et al.
Published: (2019-12-01)

Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
by: Paul S. Rennie, et al.
Published: (2013-06-01)

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.
by: Xiaotun Zhang, et al.
Published: (2011-01-01)

Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
by: Osamu Ogawa, et al.
Published: (2013-07-01)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
by: Maria Massaro, et al.
Published: (2021-09-01)

Identification of novel androgen receptor inhibitors for the treatment of castration resistant prostate cancer
by: Munuganti, Ravi Shashi Nayana
Published: (2015)

Determining the efficacy of novel anti-androgens in models of castrate resistant prostate cancer
by: O'Neill, Daniel James
Published: (2014)

Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer.
by: Jae-Kyung Myung, et al.
Published: (2017-01-01)

20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer.
by: Bo Cao, et al.
Published: (2014-01-01)

Blocking GRP/GRP-R signaling decreases expression of androgen receptor splice variants and inhibits tumor growth in castration-resistant prostate cancer
by: Thomas C. Case, et al.
Published: (2021-11-01)

Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2.
by: John M Kokontis, et al.
Published: (2014-01-01)

Correction: Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer.
by: Martina Tinzl, et al.
Published: (2018-01-01)

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
by: Pernelle Lavaud, et al.
Published: (2020-12-01)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
by: Jeanny B Aragon-Ching
Published: (2020-01-01)

CPT1A Supports Castration-Resistant Prostate Cancer in Androgen-Deprived Conditions
by: Molishree Joshi, et al.
Published: (2019-09-01)

Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
by: Oliver Sartor, et al.
Published: (2015-06-01)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
by: Rosenberg JE, et al.
Published: (2012-01-01)

Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective
by: Jo-Lynn Tan, et al.
Published: (2017-12-01)